Form 4: Heron Therapeutics CEO Converts Restricted Stock Units to Common Shares

Heron Therapeutics CEO Craig A. Collard acquired 13,797 shares of common stock through the conversion of restricted stock units, increasing his direct beneficial ownership.

Summary

• Craig A. Collard, Chief Executive Officer and Director of HERON THERAPEUTICS, INC. (HRTX), acquired 13,797 shares of common stock.
• The acquisition occurred on July 19, 2025, through the conversion of Restricted Stock Units (RSUs).
• Each restricted stock unit represents a contingent right to receive one share of common stock, with an effective acquisition price of $0 for the conversion.
• Following this transaction, Mr. Collard's direct beneficial ownership of common stock increased to 439,749 shares.
• He continues to hold 137,969 Restricted Stock Units.
• The Restricted Stock Units vest in 16 equal quarterly installments, with the vesting schedule commencing one quarter after the grant date of January 19, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine transaction, the acquisition of shares by a CEO through RSU conversion increases their direct stake, which is generally viewed favorably as it aligns management's interests with shareholders. There are no negative implications from this specific filing.

Positives

• CEO Craig A. Collard increased his direct beneficial ownership of common stock by 13,797 shares, aligning management's interests with shareholders.
• The conversion of Restricted Stock Units into common stock is a routine part of executive compensation, indicating the vesting of previously granted equity.

Future Outlook

The remaining 137,969 Restricted Stock Units held by Mr. Collard are scheduled to vest in equal quarterly installments, continuing the conversion of equity compensation into common stock over time.

Industry Context

This transaction is a standard equity compensation event for a pharmaceutical company executive, reflecting the vesting of long-term incentives. Such conversions are common across the biotech and pharmaceutical sectors as a mechanism to align executive performance with shareholder value.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders due to increased direct ownership.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Continued vesting of the remaining 137,969 Restricted Stock Units in 16 equal quarterly installments, starting one quarter after January 19, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine conversion of Restricted Stock Units (RSUs) into common stock by the CEO. Such transactions are part of standard executive compensation and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. It reinforces management's vested interest but does not provide new information to alter a 'hold' stance.

Keywords

Heron Therapeutics, HRTX, SEC Form 4, Insider Transaction, Craig Collard, Restricted Stock Units, RSU Conversion, Common Stock, CEO, Director, Equity Compensation